Ignite Creation Date:
2024-05-05 @ 12:05 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00242190
Status:
COMPLETED
Last Update Posted:
2010-11-15
First Post:
2005-10-18
Brief Title:
Gemcitabine Oxaliplatin and Radiation Therapy in Pancreatic Cancer
Sponsor:
University of Michigan Rogel Cancer Center
Organization:
University of Michigan Rogel Cancer Center
Study Overview
Official Title:
Gemcitabine Oxaliplatin and Radiation Therapy in Pancreatic Cancer
Status:
COMPLETED
Status Verified Date:
2010-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will examine a proposed research treatment which evaluates the addition of oxaliplatin a chemotherapy agent to gemcitabine another chemotherapy agent and radiation therapy for the treatment of patients with pancreatic cancer The researchers have already done studies using gemcitabine and radiation therapy together They want to build on the information they have from this previous research The researchers believe that the combination chemotherapy with radiation is worth investigating to treat pancreatic cancer They will use this study to determine what type of side effects occur with this treatment and to assess how effective the treatment is at controlling the cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None